Insys Therapeutics Inc (NASDAQ:INSY) was the recipient of unusually large options trading on Thursday. Stock traders purchased 2,156 put options on the stock. This represents an increase of approximately 1,300% compared to the typical volume of 154 put options.

Insys Therapeutics (NASDAQ:INSY) traded up $0.38 during midday trading on Monday, hitting $10.13. The stock had a trading volume of 936,473 shares, compared to its average volume of 2,640,000. The firm has a market cap of $742.70, a price-to-earnings ratio of -3.97 and a beta of 0.76. Insys Therapeutics has a fifty-two week low of $4.10 and a fifty-two week high of $15.02.

How to Become a New Pot Stock Millionaire

Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Insys Therapeutics had a negative net margin of 112.56% and a negative return on equity of 11.76%. research analysts forecast that Insys Therapeutics will post -0.63 earnings per share for the current year.

INSY has been the subject of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $14.00 price target on shares of Insys Therapeutics in a research report on Wednesday, October 11th. Zacks Investment Research cut Insys Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 19th. ValuEngine upgraded Insys Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Oppenheimer reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Sunday, November 12th. Finally, Jefferies Group dropped their price objective on Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. Insys Therapeutics has an average rating of “Hold” and a consensus price target of $9.38.

Institutional investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new position in Insys Therapeutics during the 3rd quarter worth approximately $119,000. Janney Montgomery Scott LLC acquired a new position in Insys Therapeutics during the 3rd quarter worth approximately $135,000. SG Americas Securities LLC acquired a new position in Insys Therapeutics during the 2nd quarter worth approximately $138,000. Voya Investment Management LLC acquired a new position in Insys Therapeutics during the 2nd quarter worth approximately $149,000. Finally, BNP Paribas Arbitrage SA increased its holdings in Insys Therapeutics by 213.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock worth $166,000 after purchasing an additional 8,940 shares during the last quarter. 25.35% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was reported by Marea Informative and is the sole property of of Marea Informative. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.mareainformativa.com/2018/01/29/investors-buy-high-volume-of-put-options-on-insys-therapeutics-insy-updated-updated-updated.html.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.